Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.
Location: United States, California, San Diego
Employees: 51-200
Phone: +234 904 331 6758
Total raised: $181M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 17.08.2021 | Logos Capi... | logoscapit... |
| - | Avalon Bio... | avalonbiov... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.04.2021 | Series B | $125M | Logos Capi... |
| 03.03.2021 | Series A | $56M | - |
Mentions in press and media 13
| Date | Title | Description |
| 20.03.2024 | Startup Lands $150M for Delicate Dance Between Cancer Cells & Immune Cells | Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, bringing both of them together to spark a thera... |
| 10.08.2021 | Janux Therapeutics : Successful $222.9 million IPO in June brings total funds raised in the quarter to $347.9 million (Form 8-K) | -Successful $222.9 million IPO in June brings total funds raised in the quarter to $347.9 million- -Company on-track to submit IND filings for multiple programs in 2022- -Management team strengthened with key appointments- SAN DIEGO, August... |
| 21.04.2021 | Stealthy biotech Janux nabs $125M and joins chase to direct T cells to solid tumors | The fresh capital, a Series B round of financing, comes four months after Janux revealed its Merck partnership and just seven weeks after closing a $56 million Series A round of funding. The speedy series of events sets the company up to lo... |
| 20.04.2021 | Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials | - |
| 20.04.2021 | RA Capital leads $125M for Janux in VC's latest crossover bid | Four months ago, only a short list of people had ever heard of Janux Therapeutics. Today, they have a partnership with Merck, $212 million in VC capital and, it seems, plans for an IPO. Janux announced Tuesday a $125 million ... |
| 20.04.2021 | Janux Therapeutics Closes $125M Series B | SAN DIEGO, CA, Janux Therapeutics today announced the closing of a $125 million Series B financing. >> Click here for more funding data on Janux Therapeutics >> To export Janux Therapeutics funding data to PDF and Excel, cli... |
| 03.03.2021 | Janux raises $56M to take safer T-cell engagers into the clinic | Janux Therapeutics has raised $56 million to fund development of T-cell engagers (TCEs). The series A will fund preclinical work on TROP-2 and PSMA candidates, positioning Janux to enter the clinic next year. Driven by work at companies inc... |
| 03.03.2021 | Janux Therapeutics has raised a $56M Series A led by Avalon Ventures | - |
| 03.03.2021 | Janux Therapeutics Snags $56M Series A | SAN DIEGO, CA, Janux Therapeutics snags $56M funding in Series A led by Avalon Ventures. >> Click here for more funding data on Janux Therapeutics >> To export Janux Therapeutics funding data to PDF and Excel, click here ... |
| 03.03.2021 | Janux raises $56M to take safer T-cell engagers into the clinic W e b i n a r Enabling Individuals to Act on Heart Health Insights | Janux Therapeutics has raised $56 million to fund development of T-cell engagers (TCEs). The series A will fund preclinical work on TROP-2 and PSMA candidates, positioning Janux to enter the clinic next year. BD&L Summit Deal-Making Ins... |
Show more